- Everest Medicines will obtain the clinical development and commercialization rights for Beijiexin® in the Asia-Pacific region (Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macau SAR, and Taiwan region).
- Under the agreement, Everest Medicines will pay Beijing Mabworks Biotech Co., Ltd. an upfront payment of RMB 23 million, along with sales milestone payments of up to RMB 186 million. Mabworks is eligible to receive a share of the gross profit from sales of the product in the Asia-Pacific region.
- This collaboration will further strengthen Everest Medicines’ Asia-Pacific market presence in areas such as nephrology and autoimmune diseases, creating synergies with its existing nephrology pipeline.
ShanghaiJune 4, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, the “Company”), a biopharmaceutical company focused on innovative drug R&D, clinical development, manufacturing, and commercialization, today announced a commercial licensing and collaboration agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”) to obtain the clinical development and commercialization rights for Beijiexin® (MIL62, generic name: Obinutuzumab Beta Injection) in the Asia-Pacific region (Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macau SAR, and Taiwan region).
This collaboration will further strengthen Everest Medicines’ Asia-Pacific market presence in areas such as nephrology and autoimmune diseases, creating synergies with its existing nephrology pipeline. Leveraging its proven clinical development and commercialization capabilities, the Company will accelerate the market access and commercialization of Beijiexin®, continuously unlocking growth potential in the Asia-Pacific region and advancing its long-term strategic development in the global innovative drug market.
Under the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million, along with sales milestone payments of up to RMB 186 million. Mabworks is eligible to receive a share of the gross profit from sales of the product in the Asia-Pacific region.
Beijiexin® is an innovative third-generation CD20 antibody drug independently developed by Mabworks. It was approved for marketing in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), making it the world’s first CD20 antibody approved for this disease and the first domestically produced drug for this indication in China. The new drug application (NDA) for Beijiexin® in the treatment of primary membranous nephropathy (PMN) is also under “priority review and approval” by China’s National Medical Products Administration (NMPA), with the potential to become the world’s first approved specific drug for PMN. Additionally, Beijiexin® is undergoing Phase III clinical trials covering multiple therapeutic areas, including systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune diseases.
Mr. Wu Yifang, Chairman of the Board of Everest Medicines, stated: “We are very pleased to reach this collaboration with Mabworks for Beijiexin®. Beijiexin® is not only the world’s first approved CD20 antibody for treating NMOSD but also an innovative drug with differentiated advantages and broad market potential, demonstrating significant clinical promise in nephrology and autoimmune diseases.
This collaboration will further enrich Everest Medicines’ product portfolio in nephrology and autoimmune fields, creating strong synergies with our existing pipeline. Leveraging our established and continuously strengthened clinical development and commercialization capabilities, we are confident in accelerating the development and commercialization of Beijiexin® in the Asia-Pacific region, bringing it to more patients as soon as possible, transforming innovative therapies into clinical accessibility, and further enhancing our influence in the Asia-Pacific and global innovative drug markets.”
Mr. Chen Luning, President of Mabworks, stated: “We are delighted to reach this collaboration with Everest Medicines for Beijiexin® in the Asia-Pacific region. As the world’s first approved CD20-targeted drug for treating NMOSD and a potential first-in-class specific drug for PMN, Beijiexin® boasts outstanding product competitiveness and market potential. Since its launch, Beijiexin® has achieved excellent commercial results in mainland China. This collaboration will further strengthen Beijiexin®‘s commercial network and brand influence across the Asia-Pacific market, bringing ‘new’ hope to more patients with nephrology and autoimmune diseases outside mainland China.”
Beijiexin® has demonstrated significant clinical and therapeutic value in nephrology and multiple autoimmune diseases, with broad potential for indication expansion. Its ongoing development and progress in NMOSD, PMN, and SLE are expected to offer patients more innovative treatment options.
NMOSD is a central nervous system autoimmune disease with high relapse rates and high disability rates, commonly affecting young and middle-aged women. The disease typically has an acute or subacute onset and can progress rapidly, with approximately 90% of patients experiencing relapse within three years, potentially leading to blindness or paralysis in severe cases. Beijiexin® has shown significant advantages in reducing relapse risk as a monotherapy, with excellent efficacy data highlighting its clinical value and treatment convenience as a standalone therapy.
PMN is the most common pathological type of adult kidney disease, with approximately 30%-40% of patients potentially progressing to end-stage renal disease within 5-15 years. Currently, there are no approved specific drugs globally. Phase III clinical studies have shown that Beijiexin® monotherapy demonstrates significant advantages in various indicators, including complete clinical remission, complete immunological remission, and clinical remission. Additionally, Beijiexin® has a favorable safety and tolerability profile, with a convenient dosing schedule—patients only need intravenous injections once every six months after initial treatment—significantly reducing treatment burden and improving long-term compliance.
SLE is a chronic systemic autoimmune disease. Beijiexin® is currently in Phase III clinical studies, with a long dosing interval advantage of 24-28 weeks, meeting patients’ clinical needs for long-acting treatment regimens and potentially offering better treatment options for SLE patients.
About Beijiexin®
Beijiexin® for the treatment of primary membranous nephropathy (PMN) was included in the “Breakthrough Therapy” drug category by China’s National Medical Products Administration in October 2025, becoming the first domestically produced drug to receive this designation in the nephrology field. Its NDA is currently under “priority review and approval,” with the potential to become the world’s first approved specific drug for treating PMN.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on innovative drug R&D, clinical development, manufacturing, and commercialization, dedicated to meeting unmet medical needs in the global market. The management team of Everest Medicines possesses deep expertise and extensive experience at leading pharmaceutical companies in China and globally. The company has a commercial-scale global manufacturing base in Jiashan, Zhejiang Province, and has established a comprehensive GMP quality management system in accordance with Chinese, U.S., and EU standards.
The company focuses on therapeutic areas such as autoimmune diseases, ophthalmology, acute and critical illnesses, and CKM (cardiovascular, kidney, and metabolic) diseases. It has built a commercialization platform encompassing a full-channel commercial system and full lifecycle commercialization capabilities. Leveraging its self-developed mRNA platform with global rights, the company continues to advance existing pipelines, including mRNA in vivo CAR-T and mRNA tumor vaccines, while expanding R&D capabilities through introductions and ecosystem incubation of potential platforms, strengthening global layout, and accelerating international development. For more information, please visit the company’s website: www.everestmedicines.com.
About Mabworks
Beijing Mabworks Biotech Co., Ltd. focuses on the R&D and industrialization of innovative antibody-targeted drugs, committed to bringing innovative treatment options to patients with autoimmune diseases and tumors. The company translates scientific breakthroughs in immunology and biology into novel antibody-targeted therapies, conducting product development and technological innovation for various autoimmune diseases and tumor markets with significant unmet medical needs and market potential. The company is a national high-tech enterprise, a Beijing specialized and new “Little Giant” enterprise, a Beijing key laboratory, and a Beijing engineering laboratory, and has established a postdoctoral workstation and an academician expert workstation.
Forward-Looking Statements
The information released in this press release may contain certain forward-looking statements, based on the Company’s or management’s current views, beliefs, and expectations regarding the Company’s business operations and financial condition at the time the statements are made. These may use words such as “will,” “expect,” “anticipate,” “forecast,” “intend,” “plan,” “believe,” “estimate,” “confident,” and other similar expressions. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the Company’s control and difficult to predict. Therefore, actual results may differ materially from the information contained in the forward-looking statements due to various factors and assumptions, including future changes and developments in our business, competitive environment, political, economic, legal, and social conditions. The Company, its subsidiaries, directors, management, consultants, and agents do not assume and disclaim any obligation to update the forward-looking statements contained in this release to reflect subsequent information, future events, or circumstances, except as required by law.